000 03613nam a22003975i 4500
001 309735
003 MX-SnUAN
005 20160429160321.0
007 cr nn 008mamaa
008 150903s2005 sz | o |||| 0|eng d
020 _a9783764374143
_99783764374143
024 7 _a10.1007/3764374144
_2doi
035 _avtls000362746
039 9 _a201509030401
_bVLOAD
_c201404121557
_dVLOAD
_c201404091335
_dVLOAD
_y201402211057
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aRC261-271
100 1 _aHerrling, Paul L.
_eeditor.
_9350181
245 1 0 _aAdvances in Targeted Cancer Therapy /
_cedited by Paul L. Herrling, Alex Matter, Richard M. Schultz.
264 1 _aBasel :
_bBirkhäuser Basel,
_c2005.
300 _avii, 303 páginas
_brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
490 0 _aProgress in Drug Research ;
_v63
500 _aSpringer eBooks
505 0 _aDawn of a new era in molecular cancer therapeutics -- Obtacles and opportunities in the clinical development of targeted therapeutics -- Tumor models for preclinical development of targeted agents -- Angiogenesis inhibitors: What is the clinical future? -- Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy -- Cell survival signaling during apoptosis: Implications in drug resistance and anti-cancer therapeutic development -- Targeted histone deacetylase inhibition for cancer prevention and therapy -- Inhibitors of cyclin-dependent kinase modulators for cancer therapy -- Targeting cyclooxygenase-2 for cancer prevention and treatment -- Antisense approaches in drug discovery and development -- Preclinical development of Alimta™ (Pemetrexed, LY231514), a multitargeted antifolate.
520 _aThere have been tremendous advances in our understanding of molecular and tumor biology during the past few years. In the field of cancer therapeutics, it is expected that cytotoxic drug approaches will be gradually replaced with treatments based on biological targeted approaches. Hopefully these new targeted therapies will significantly increase efficacy and lack the devastating and troublesome side effects elicited by cytotoxic chemotherapy. This volume is the first book to cover the general topic of targeted cancer therapy. It presents a range of targets such as tumor angiogenesis, cell cycle control and cell signalling, COX-2, apoptosis/cell survival, invasion and metastasis and approaches like kinase inhibitors, antisense, and antibody-based therapeutics. The emphasis is on preclinical development, including target validation, development of biomarkers, strategies for combination approaches, and development of resistance. The particular challenges involved in translating these data to clinical application are discussed. This volume should be of broad general interest to researchers and clinicians involved in cancer therapy as well as other scientists interested in current strategies for cancer treatment.
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700 1 _aMatter, Alex.
_eeditor.
_9350182
700 1 _aSchultz, Richard M.
_eeditor.
_9350183
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9783764371746
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/3-7643-7414-4
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c309735
_d309735